These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35157705)

  • 1. Chorioallantoic membrane (CAM) assay to study treatment effects in diffuse intrinsic pontine glioma.
    Power EA; Fernandez-Torres J; Zhang L; Yaun R; Lucien F; Daniels DJ
    PLoS One; 2022; 17(2):e0263822. PubMed ID: 35157705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK2 inhibitors display beneficial effects in preclinical models of
    Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
    Commun Biol; 2019; 2():156. PubMed ID: 31098401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
    Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
    Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
    Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
    Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies.
    Weisbrod LJ; Thiraviyam A; Vengoji R; Shonka N; Jain M; Ho W; Batra SK; Salehi A
    Cancer Lett; 2024 May; 590():216876. PubMed ID: 38609002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
    Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
    Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
    Fons NR; Sundaram RK; Breuer GA; Peng S; McLean RL; Kalathil AN; Schmidt MS; Carvalho DM; Mackay A; Jones C; Carcaboso ÁM; Nazarian J; Berens ME; Brenner C; Bindra RS
    Nat Commun; 2019 Aug; 10(1):3790. PubMed ID: 31439867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets.
    Zhu X; Lazow MA; Schafer A; Bartlett A; Senthil Kumar S; Mishra DK; Dexheimer P; DeWire M; Fuller C; Leach JL; Fouladi M; Drissi R
    Acta Neuropathol Commun; 2021 Jan; 9(1):14. PubMed ID: 33431066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
    Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
    Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laminin-associated integrins mediate Diffuse Intrinsic Pontine Glioma infiltration and therapy response within a neural assembloid model.
    Sinha S; Huang MS; Mikos G; Bedi Y; Soto L; Lensch S; Ayushman M; Bintu L; Bhutani N; Heilshorn SC; Yang F
    Acta Neuropathol Commun; 2024 May; 12(1):71. PubMed ID: 38706008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
    Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
    Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas.
    Schramm K; Iskar M; Statz B; Jäger N; Haag D; Słabicki M; Pfister SM; Zapatka M; Gronych J; Jones DTW; Lichter P
    Neuro Oncol; 2019 Jul; 21(7):867-877. PubMed ID: 30943283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG).
    Werbrouck C; Evangelista CCS; Lobón-Iglesias MJ; Barret E; Le Teuff G; Merlevede J; Brusini R; Kergrohen T; Mondini M; Bolle S; Varlet P; Beccaria K; Boddaert N; Puget S; Grill J; Debily MA; Castel D
    Clin Cancer Res; 2019 Nov; 25(22):6788-6800. PubMed ID: 31481512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma.
    Arms LM; Duchatel RJ; Jackson ER; Sobrinho PG; Dun MD; Hua S
    J Control Release; 2024 Jun; 370():835-865. PubMed ID: 38744345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The intersect of neurosurgery with diffuse intrinsic pontine glioma.
    Kuzan-Fischer CM; Souweidane MM
    J Neurosurg Pediatr; 2019 Dec; 24(6):611-621. PubMed ID: 31786541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a clinical scale for assessment of patients with diffuse intrinsic pontine glioma (DIPG) receiving experimental therapy: the PONScore.
    Hollingworth MA; Zacharoulis S
    J Neurooncol; 2020 Sep; 149(2):263-272. PubMed ID: 32902768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
    Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
    Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival.
    Silva-Evangelista C; Barret E; Ménez V; Merlevede J; Kergrohen T; Saccasyn A; Oberlin E; Puget S; Beccaria K; Grill J; Castel D; Debily MA
    Oncogene; 2019 Sep; 38(38):6479-6490. PubMed ID: 31324890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
    An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.